Anna J Nichols1,2, Adrianna Gonzalez1, Emily S Clark3, Wasif N Khan3, Alyx C Rosen4, Wellington Guzman1, Harold Rabinovitz1,5, Evangelos V Badiavas1, Robert S Kirsner1,2, Tim Ioannides1,6. 1. Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida. 2. Department of Dermatology and Cutaneous Surgery, Sylvester Comprehensive Cancer Center, Miami, Florida. 3. Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida. 4. Skin Institute of South Florida & Hollywood Dermatology, Hollywood. 5. Skin and Cancer Associates, Plantation, Florida. 6. Treasure Coast Dermatology, Port St Lucie, Florida.
Abstract
Importance: Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. Objective: To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. Design, Setting, and Participants: A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. Main Outcomes and Measures: Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. Results: All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. Conclusions and Relevance: This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.
Importance: Squamous cell carcinoma (SCC) is the second most common form of skin cancer, and its incidence is increasing. When surgical management is not an option, finding a safe and efficacious treatment is a challenge. Mounting evidence suggests that the human papillomavirus (HPV) is involved in the pathogenesis of some SCCs. Objective: To assess whether the 9-valent HPV vaccine could be an effective treatment strategy for cutaneous SCC. Design, Setting, and Participants: A woman in her 90s with multiple, inoperable cutaneous basaloid SCCs was successfully treated at a university-based outpatient dermatology clinic with a combination of systemic and intratumoral delivery of the 9-valent HPV vaccine from March 17, 2016, through February 27, 2017, and then followed up through May 21, 2018. Main Outcomes and Measures: Reduction in tumor size and number after a combination of systemic and intratumoral administration of the HPV vaccine. Results: All tumors resolved 11 months after the first intratumoral injection of the vaccine. The patient remained free of tumors at the end of follow-up. Conclusions and Relevance: This is the first report, to our knowledge, of complete regression of a cutaneous malignant tumor after combined systemic and direct intratumoral injection of the 9-valent HPV vaccine. This report suggests that the HPV vaccine may have therapeutic utility for SCCs in patients who are poor surgical candidates, have multiple lesions, or defer surgery.
Authors: Anna J Nichols; Amber Heyna Allen; Shahjahan Shareef; Evangelos V Badiavas; Robert S Kirsner; Tim Ioannides Journal: JAMA Dermatol Date: 2017-06-01 Impact factor: 10.282
Authors: Jad Chahoud; Adele Semaan; Yong Chen; Ming Cao; Alyssa G Rieber; Peter Rady; Stephen K Tyring Journal: JAMA Dermatol Date: 2016-12-01 Impact factor: 10.282
Authors: Margaret R Karagas; Heather H Nelson; Peter Sehr; Tim Waterboer; Therese A Stukel; Angeline Andrew; Adele C Green; Jan Nico Bouwes Bavinck; Ann Perry; Steven Spencer; Judy R Rees; Leila A Mott; Michael Pawlita Journal: J Natl Cancer Inst Date: 2006-03-15 Impact factor: 13.506
Authors: Cinzia Borgogna; Simone Lanfredini; Alberto Peretti; Marco De Andrea; Elisa Zavattaro; Enrico Colombo; Marco Quaglia; Renzo Boldorini; Umberto Miglio; John Doorbar; Jan N Bouwes Bavinck; Koen D Quint; Maurits N C de Koning; Santo Landolfo; Marisa Gariglio Journal: Mod Pathol Date: 2014-01-03 Impact factor: 7.842
Authors: Margaret R Karagas; Tim Waterboer; Zhongze Li; Heather H Nelson; Kristina M Michael; Jan Nico Bouwes Bavinck; Ann E Perry; Steven K Spencer; Janet Daling; Adele C Green; Michael Pawlita Journal: BMJ Date: 2010-07-08